Ovarian Cancer News and Research

RSS
Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
ReSisTrace: Unveiling Pre-Existing Treatment Resistance in Cancer Cells

ReSisTrace: Unveiling Pre-Existing Treatment Resistance in Cancer Cells

Imec's Microfluidics Chip Shows Promise in Cancer Immune Profiling

Imec's Microfluidics Chip Shows Promise in Cancer Immune Profiling

Researchers Develop Drug Targeting lncRNA TUG1 to Control Brain Tumor Growth in Mice

Researchers Develop Drug Targeting lncRNA TUG1 to Control Brain Tumor Growth in Mice

Pre-Targeted Radioimmunotherapy System Cures Fatal Ovarian Cancer in Preclinical Study

Pre-Targeted Radioimmunotherapy System Cures Fatal Ovarian Cancer in Preclinical Study

Unknown Membrane Proteins for Ovarian Cancer Diagnosis

Unknown Membrane Proteins for Ovarian Cancer Diagnosis

Location-Dependent Gene Expression in Ovarian Cancer: Insights from 3-D Models

Location-Dependent Gene Expression in Ovarian Cancer: Insights from 3-D Models

Designing a Lipid Nanoparticle to Safely Deliver mRNA to the Pancreas

Designing a Lipid Nanoparticle to Safely Deliver mRNA to the Pancreas

"Visual Biochemistry" Approach to Understand How the BRCA2 Protein Binds and Interacts with DNA

"Visual Biochemistry" Approach to Understand How the BRCA2 Protein Binds and Interacts with DNA

Curcumin could enhance ovarian cancer treatments

Curcumin could enhance ovarian cancer treatments

Women over 50 with genetic BRCA1 or BRCA2 mutation face a high risk of cancer

Women over 50 with genetic BRCA1 or BRCA2 mutation face a high risk of cancer

Novel model system helps studying human ovarian biology

Novel model system helps studying human ovarian biology

Novel approach removes the barriers of lifesaving cancer genetic services

Novel approach removes the barriers of lifesaving cancer genetic services

Robust new method accurately identifies eight antidepressants

Robust new method accurately identifies eight antidepressants

Treating ovarian cancer with immunotherapy involving CAR T cells

Treating ovarian cancer with immunotherapy involving CAR T cells

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy effective in mice with ovarian cancer

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Point-of-care program boosts genetic testing for prostate cancer

Point-of-care program boosts genetic testing for prostate cancer

Importance of localizing BRCA gene mutations for ovarian cancer treatment

Importance of localizing BRCA gene mutations for ovarian cancer treatment

WEHI receives $2.5 million fund to develop personalized cancer treatments

WEHI receives $2.5 million fund to develop personalized cancer treatments

New type of chip could lead to earlier and more targeted treatment for cancer

New type of chip could lead to earlier and more targeted treatment for cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.